## Supplementary Table S4: Statistical analysis clinical characteristics pure small fiber neuropathy patients

| Variable | No Variant | Variant | SCN9A | SCN10A | SCN11A | Main comparison (alpha < 0.05 ) | Post-hoc analyses (alpha < 0.0083) |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  |  |  |  |  | No variant vs. variant | SCN9A vs no variant | SCN10A vs no variant | SCN11A vs no variant | SCN9A vs. SCN10A | SCN9A vs. SCN11A | SCN10A vs. SCN11A |
| TTT (total abnormal) | 932/1000 (93.2\%) | 122/132 (92.4\%) | 52/57 (91.2\%) | 41/42 (97.6\%) | 28/32 (87.5\%) | 0.741 | 0.587* | 0.518* | 0.274* | 0.237* | 0.717* | 0.159* |
| IENFD (total abnormal) | 327/1003 (32.6\%) | 50/132 (37.9\%) | 23/57 (40.4\%) | 17/42 (40.5\%) | 9/32 (28.1\%) | 0.226 | 0.226 | 0.287 | 0.594 | 0.990 | 0.249 | 0.270 |
| Abnormal pain sensation (total) | 224/407 (55.0\%) | 33/52 (63.5\%) | 11/21 (52.4\%) | 7/12 (58.3\%) | 15/19 (78.9\%) | 0.249 | 0.811 | 0.821 | 0.040 | 0.741 | 0.079 | 0.253* |
| Erythromelalgia (total present) | 265/1004 (26.4\%) | 43/132 (32.6\%) | 25/57 (43.9\%) | $7 / 42$ (16.7\%) | 10/32 (31.3\%) | 0.133 | 0.004 | 0.159 | 0.540 | 0.004 | 0.243 | 0.140 |
| Itch (total present) | 117/1004 (11.7\%) | 13/131 (9.9\%) | 5/56 (8.9\%) | 4/42 (9.5\%) | 4/32 (12.5\%) | 0.559 | 0.534 | 0.810* | 0.782* | 1.000* | 0.718* | 0.720* |
| Cramps (total present) | 166/1004 (16.5\%) | 25/131 (19.1\%) | 8/56 (14.3\%) | 8/42 (19.0\%) | 9/32 (28.1\%) | 0.463 | 0.658 | 0.668 | 0.085 | 0.528 | 0.114 | 0.467 |
| Positive family history (total) | 225/916 (24.6\%) | 41/121 (33.9\%) | 19/53 (35.8\%) | 13/38 (34.2\%) | 9/30 (30.0\%) | 0.027 | 0.066 | 0.178 | 0.497 | 0.872 | 0.588 | 0.712 |
| Increase of pain by warmth (total) | 178/576 (30.9\%) | 33/73 (45.2\%) | 18/37 (48.6\%) | 6/17 (35.3\%) | 9/19 (47.4\%) | 0.014 | 0.025 | 0.700 | 0.128 | 0.359 | 0.928 | 0.463 |
| Increase of pain by cold (total) | 245/541 (45.3\%) | 36/64 (56.3\%) | 14/29 (48.3\%) | 13/19 (68.4\%) | 9/16 (56.3\%) | 0.096 | 0.753 | 0.047 | 0.386 | 0.169 | 0.608 | 0.458 |
| Increase of pain by exercise (total) | 470/661 (71.1\%) | 62/91 (68.1\%) | 25/36 (69.4\%) | 19/29 (65.5\%) | 18/26 (69.2\%) | 0.559 | 0.831 | 0.517 | 0.836 | 0.736 | 0.986 | 0.769 |
| Increase of pain by rest (total) | 271/408 (66.4\%) | 38/57 (66.7\%) | 14/23 (60.9\%) | 14/18 (77.8\%) | 10/16 (62.5\%) | 0.971 | 0.584 | 0.316 | 0.745 | 0.248 | 0.918 | 0.457* |
| NPS1 (total score 4 or higher) | 709/800 (88.6\%) | 98/112 (87.5\%) | 47/50 (94.0\%) | 29/35 (82.9\%) | 21/26 (80.8\%) | 0.727 | 0.240 | 0.282* | 0.213* | 0.152* | 0.114* | 1.000* |
| NPS2 | 692/803 (86.2\%) | 101/112 (90.2\%) | 46/50 (92.0\%) | 32/37 (86.5\%) | 22/24 (91.7\%) | 0.243 | 0.242 | 0.957 | 0.761* | 0.486* | 1.000* | 0.694* |
| NPS3 | 692/818 (84.6\%) | 99/113 (87.6\%) | 45/50 (90.0\%) | 32/37 (86.5\%) | 21/25 (84.0\%) | 0.401 | 0.300 | 0.755 | 1.000* | 0.738* | 0.470* | 1.000* |
| NPS4 | 589/763 (77.2\%) | 82/111 (73.9\%) | 36/50 (72.0\%) | 24/35 (68.6\%) | 21/25 (84.0\%) | 0.439 | 0.399 | 0.237 | 0.423 | 0.733 | 0.251 | 0.174 |
| NPS5 | 452/817 (55.3\%) | 68/116 (58.6\%) | 28/52 (53.8\%) | 23/38 (60.5\%) | 16/25 (64.0\%) | 0.504 | 0.835 | 0.528 | 0.390 | 0.528 | 0.399 | 0.781 |
| NPS6 | 548/816 (67.2\%) | 79/113 (69.9\%) | 36/52 (69.2\%) | 23/36 (63.9\%) | 19/24 (79.2\%) | 0.558 | 0.757 | 0.683 | 0.216 | 0.600 | 0.368 | 0.206 |
| NPS7 | 350/818 (42.8\%) | 58/117 (49.6\%) | 19/53 (3.8\%) | 23/38 (60.5\%) | 16/25 (64.0\%) | 0.166 | 0.322 | 0.031 | 0.035 | 0.020 | 0.020 | 0.781 |
| NPS9 | 730/769 (94.9\%) | 101/105 (96.2\%) | 46/47 (97.9\%) | 33/35 (94.3\%) | 21/22 (95.5\%) | 0.575 | 0.723* | 0.697* | 1.000* | 0.573* | 0.539* | 1.000* |
| NPS10a | 673/769 (87.5\%) | 95/109 (87.2\%) | 42/48 (87.5\%) | 32/36 (88.9\%) | 21/24 (87.5\%) | 0.915 | 0.997 | 1.000* | 1.000* | 1.000* | 1.000* | 1.000* |
| NPS10b | 653/773 (84.5\%) | 89/106 (84.0\%) | 41/47 (87.2\%) | 28/35 (80.0\%) | 20/23 (87.0\%) | 0.891 | 0.611 | 0.477 | 1.000* | 0.375 | 1.000* | 0.725* |
| SFN-SIQ1 (total score 2 or higher) | 681/840 (81.1\%) | 91/113 (80.5\%) | 38/50 (76.0\%) | 28/35 (80.0\%) | 24/27 (88.9\%) | 0.891 | 0.377 | 0.874 | 0.305 | 0.663 | 0.173 | 0.491* |
| SFN-SIQ2 | 535/839 (63.8\%) | 72/117 (61.5\%) | 29/51(56.9\%) | 22/38 (57.9\%) | 20/27 (74.1\%) | 0.639 | 0.320 | 0.462 | 0.272 | 0.922 | 0.135 | 0.179 |
| SFN-SIQ3 | 507/842 (60.2\%) | 69/114 (60.5\%) | 32/52 (61.5\%) | 17/35 (48.6\%) | 20/26 (76.9\%) | 0.949 | 0.850 | 0.169 | 0.086 | 0.232 | 0.174 | 0.025 |
| SFN-SIQ4 | 574/845 (67.9\%) | 78/117 (66.7\%) | 33/52 (63.5\%) | 23/37 (62.2\%) | 22/27 (81.5\%) | 0.784 | 0.504 | 0.463 | 0.136 | 0.900 | 0.099 | 0.095 |
| SfN-SIQ 5 | 543/843 (64.4\%) | 80/119 (67.2\%) | 34/53 (64.2\%) | 28/38 (73.7\%) | 17/27 (63.0\%) | 0.547 | 0.969 | 0.242 | 0.877 | 0.336 | 0.917 | 0.356 |
| SfN-SIQ6 | 673/844 (79.7\%) | 98/118 (83.1\%) | 42/52 (80.8\%) | 33/38 (86.8\%) | 22/27 (81.5\%) | 0.398 | 0.858 | 0.284 | 0.824 | 0.445 | 0.939 | 0.729* |
| SFN-SIQ7 | 595/840 (70.8\%) | 81/118 (68.5\%) | 35/52 (67.3\%) | 26/38 (68.4\%) | 20/27 (74.1\%) | 0.625 | 0.588 | 0.749 | 0.715 | 0.911 | 0.535 | 0.621 |
| SfN-SIQ8 | 567/838 (67.7\%) | 77/117 (65.8\%) | 33/52 (63.5\%) | 25/38 (65.8\%) | 18/26 (69.2\%) | 0.689 | 0.531 | 0.809 | 0.866 | 0.820 | 0.614 | 0.773 |
| SFN-SIQ9 | 587/841 (69.8\%) | 82/117 (70.1\%) | 34/52 (65.4\%) | 26/37 (70.3\%) | 21/27 (77.8\%) | 0.949 | 0.502 | 0.951 | 0.373 | 0.628 | 0.256 | 0.502 |
| SFN-SIQ10 | 662/844 (78.4\%) | 91/116 (78.4\%) | 36/51 (70.6\%) | 30/38 (78.9\%) | 24/26 (92.3\%) | 0.998 | 0.189 | 0.940 | 0.088 | 0.373 | 0.030 | 0.181* |
| SFN-SIQ11 | 771/834 (92.4\%) | 108/116 (93.1\%) | 46/50 (92.0\%) | 35/38 (92.5\%) | 26/27 (96.3\%) | 0.801 | 0.786* | 0.761* | 0.714* | 1.000* | 0.652* | 0.636* |
| SFN-SIQ12 | 626/843 (74.3\%) | 88/118 (74.6\%) | 38/52 (73.1\%) | 27/38 (71.1\%) | 22/27 (81.5\%) | 0.941 | 0.850 | 0.659 | 0.397 | 0.832 | 0.407 | 0.336 |
| SFN-SIQ13 | 732/839 (87.2\%) | 97/118 (82.2\%) | 44/52 (84.6\%) | 29/38 (76.3\%) | 23/27 (85.2\%) | 0.132 | 0.583 | 0.052 | 0.768* | 0.320 | 1.000* | 0.378 |
|  |  |  |  |  |  | Independent T -Test |  |  |  |  |  |  |
| Mean age (in years $\pm$ SD) | $52.22 \pm 12.990$ | $51.26 \pm 14.506$ | $48.74 \pm 15.202$ | $53.48 \pm 13.204$ | $52.47 \pm 14.728$ | $0.468^{\text {r }}$ | $0.095^{\text {\# }}$ | 0.541 | 0.917 | 0.109 | 0.264 | 0.758 |
| Mean debut age (in years $\pm$ S ) | $46.03 \pm 14.457$ | $45.84 \pm 15.483$ | $42.12 \pm 16.722$ | $48.74 \pm 13.895$ | $48.09 \pm 14.340$ | 0.884 | $0.091^{\text {\# }}$ | 0.235 | 0.428 | 0.040 | 0.093 | 0.846 |
| VAS maximal ( $\pm$ SD) | $77.52 \pm 21.833$ | $78.26 \pm 18.610$ | $79.76 \pm 18.337$ | $77.03 \pm 19.095$ | $78.00 \pm 19.305$ | 0.754 | 0.534 | 0.903 | 0.918 | 0.548 | 0.726 | 0.857 |

TTT: temperature threshold testing; IENFD: intraepidermal nerve fiber density; SD: standard deviation; *Fisher exact test; "equal variances not assumed. The green shaded values are statistically significant.
One patient with both an SCN9A and SCN11A variant was excluded in the separate analysis.
 point scale ( $0=$ not applicable to the experienced pain and $10=$ in the most severe form applicable to the experienced pain). An NPS score >3 is considered as a relevant pain quality
 $10=$ sensitive skin legs; 11 = burning feet; $12=$ intolerance for sheets; $13=$ restless legs. The answer options of the SFN-SIQ include 'never $=1$ ', 'sometimes =2', 'often = $3^{\prime}$ ' and 'always $=4$ '. A symptom is considered to be present when the score is $>1$. VAS: visual analogue scale. VAS is ranging from $0-100(0=$ no pain and $100=$ the worst possible pain $)$.

